The Caring Ambassadors Program provides this website to help you and your loved ones understand your disease
and some of the healthcare option available to you.

Our three main methods to fight lung cancer are to Empower patients and providers with access to free educational materials, and resources; to Educate communities about the importance of screening and to share current information with patients and their families; and to Advocate for access to screening and treatment for lung cancer for all communities. Knowledge empowers you to ask the necessary questions to become your own best advocate. When your questions have been asked and answered, you and your healthcare providers will be in the best possible situation to determine the best treatment approach for you.

Newly Diagnosed?

Caring Ambassadors has  released Lung Cancer Choices 3rd Edition, an amazing resource for those diagnosed with lung cancer.

Are you a Caregiver?

Caregiver Choicesa resource for all those who find themselves in the role of caregiver for someone who has been diagnosed with lung cancer.

Week Ending February 11, 2019

From One Cancer to Many: How NSCLC Treatment Has Changed in 20 Years
“Reflecting on the past 20 years of advances in non–small cell lung cancer (NSCLC), I am struck by how long a period went by with so little progress. Of course, today NSCLC treatment is changing at a breakneck pace, with new advancements presented at seemingly every major meeting and newly approved drugs emerging multiple times per year.”

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
“Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma.”

Q&A: A new focus on small cell lung cancer
“Dr. David MacPherson discusses the state of small cell lung cancer research, how his lab is tackling this deadly disease, and what makes him excited for the future”

Researchers analyze efficacy and toxicity of ICIs in older patients with NSCLC
“Older adults with advanced non-small cell lung cancer (NSCLC) may be particularly vulnerable to adverse events, therapy discontinuation, glucocorticoid rescue, and hospitalization during treatment with immune checkpoint inhibitors (ICIs), according to a recent study published in the Journal of the American Geriatrics Society.”

Study: Lung Cancer Risk Drops Dramatically Within 5 Years Of Quitting Smoking
“The sooner you put out your final cigarette for good, the better. A study finds that the risk of lung cancer drops significantly within five years of quitting smoking.”

Simulating your cancer treatment on a computer
“In ten years, computers will be able to propose the most suitable cancer treatment for you. The idea is to simulate how all possible combinations of existing cancer treatments will work on your particular tumour.”

Expert Highlights Current Treatment Approaches in EGFR+ NSCLC
“Although immunotherapy has challenged the thought process behind treating many solid and hematologic tumors, physicians should proceed with caution when using these agents in patients with non–small cell lung cancer (NSCLC) who have driver mutations, such as EGFR, explained Rogerio Lilenbaum, MD.”

Padda Discusses Progress With Osimertinib and Next Steps in EGFR+ NSCLC
“Osimertinib (Tagrisso) has effectively overcome the T790M resistance mechanism associated with earlier-generation EGFR TKIs, but patients with EGFR-positive non–small cell lung cancer (NSCLC) are still experiencing disease progression on the third-generation drug, said Sukhmani Padda, MD.”

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
“Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with no targeted therapeutic options and in which chemotherapy is only partially effective. Previous studies indicated that SCLC growth is suppressed by drugs that inhibit the histone lysine demethylase LSD1.”

Doctors dramatically reduce racial disparities in early-stage lung cancer treatment
“Results from a study published in the journal Cancer Medicine show that a pragmatic system-based intervention within cancer treatment centers can eliminate existing disparities in treatment and outcomes for black patients with early-stage lung cancer across the U.S.”

Patients’ Satisfaction With Chemotherapy Influences Health-Related Quality of Life in Advanced Thoracic Cancer
“According to results of a Dutch prospective study of patients with locally advanced or metastatic thoracic cancer receiving chemotherapy with pemetrexed, lower patient satisfaction with treatment was associated with lower health-related quality of life (HRQoL) scores and higher frequencies of low-grade adverse events. This study was published online in Supportive Care in Cancer.”

Lung Cancer May Be Sniffed Out Earlier with Graphene e-Nose
“Lung cancer may not be the first thought that crosses the mind when talking about breathalyzer tests. But, what if lung cancer detection were as easy as breathing into a device? That is the goal of a group of researchers from the University of Exeter who have recently taken a new approach to e-nose technology integrated with multi-layered graphene for early detection of lung cancer.”

For EGFR- and ALK-Driven Lung Cancers, Use ‘Best Drug First’

Order Educational Materials

Free Brochures & Materials

Be Empowered by the Journey of a Lung Cancer Sur-THRIVE-er